Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-1042 · 1 trial · 1 indication
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Number of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed.
The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior.
Number of participants with abnormal change in physical examinations in areas like cardiovascular, respiratory, and neurological systems will be assessed.
12-lead resting ECG will be recorded.
Number of participants with abnormal change in clinical laboratory test results like hematology will be assessed.
Cmax of ABBV-1042
Tmax of ABBV-1042
β of ABBV-1042
t1/2 of ABBV-1042
AUCt of ABBV-1042
AUCinf of ABBV-1042
| Arm | Type | Description |
|---|---|---|
| ABBV-1042 or Placebo-Group 1 | EXPERIMENTAL | Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
| ABBV-1042 or Placebo-Group 2 | EXPERIMENTAL | Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
| ABBV-1042 or Placebo-Group 3 | EXPERIMENTAL | Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
| ABBV-1042 or Placebo-Group 4 | EXPERIMENTAL | Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
| ABBV-1042 or Placebo-Group 5 | EXPERIMENTAL | Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
| ABBV-1042 or Placebo-Group 6 | EXPERIMENTAL | Participants will receive an oral dose of ABBV-1042 or placebo on day 1. |
| Name | Type | Description |
|---|---|---|
| ABBV-1042 | DRUG | Oral Solution |
| Placebo | DRUG | Oral Solution |
Inclusion Criteria: * BMI is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters. * Body weight ˃ 45 kg at the time of screening and upon initial confinement. * A condition of general good hea...
ABBV-1042 is an investigational small molecule developed by AbbVie Inc. (ticker ABBV). It is in Phase 1 clinical development, and the specific disease or condition it is intended to treat has not been publicly disclosed. The only completed study of ABBV-1042 enrolled healthy adult volunteers rather than patients.
ABBV-1042 is made by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the developer and sponsor of the compound's clinical program. ABBV-1042 is an early-stage small molecule asset in the company's pipeline.
ABBV-1042 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials of ABBV-1042 are currently listed. The compound is investigational and has not been established as a marketed or approved therapy.
ABBV-1042 has been studied in one completed Phase 1 trial, NCT07222709, titled a study to assess adverse events and how oral ABBV-1042 moves through the body of healthy adult participants. The trial enrolled 36 healthy volunteers in the United States, was randomized, double-blind, and controlled, and included participants aged 18 years and older of all sexes.
The completed Phase 1 study of ABBV-1042, NCT07222709, was a randomized, double-blind, controlled trial in 36 healthy adult volunteers in the United States. It assessed adverse events and how oral ABBV-1042 moves through the body. Participants were 18 years or older and of all sexes, and the study was not biomarker selected.